These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 1372969

  • 1. [Treatment of carcinoid syndrome with a somatostatin analogue].
    Döbrönte Z, Stöckert A, Végh G, Varga L.
    Orv Hetil; 1992 Mar 22; 133(12):731-4. PubMed ID: 1372969
    [Abstract] [Full Text] [Related]

  • 2. [A prolonged-action somatostatin analog and carcinoid syndrome].
    Chayvialle JA.
    Bull Acad Natl Med; 1989 May 22; 173(5):643-50; discussion 650-1. PubMed ID: 2478266
    [Abstract] [Full Text] [Related]

  • 3. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
    Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG.
    N Engl J Med; 1986 Sep 11; 315(11):663-6. PubMed ID: 2427948
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A single-centre experience with octreotide in the treatment of different hypersecretory syndromes in patients with functional gastroenteropancreatic neuroendocrine tumors.
    Berković MC, Altabas V, Herman D, Hrabar D, Goldoni V, Vizner B, Zjacić-Rotkvić V.
    Coll Antropol; 2007 Jun 11; 31(2):531-4. PubMed ID: 17847934
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Uneventful spinal anesthesia for a patient with carcinoid syndrome managed with long-acting octreotide.
    Orbach-Zinger S, Lombroso R, Eidelman LA.
    Can J Anaesth; 2002 Jun 11; 49(7):678-81. PubMed ID: 12193484
    [Abstract] [Full Text] [Related]

  • 10. The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome.
    Oberg K, Norheim I, Theodorsson E, Ahlman H, Lundqvist G, Wide L.
    J Clin Endocrinol Metab; 1989 Apr 11; 68(4):796-800. PubMed ID: 2466045
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Treatment of the carcinoid syndrome with somatostatin, salmon calcitonin, or octreotide.
    Antonelli A, Gambuzza C, Bertoni F, Baschieri L.
    Clin Ther; 1992 Apr 11; 14(2):178-84. PubMed ID: 1377097
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome.
    Saslow SB, O'Brien MD, Camilleri M, von der Ohe M, Homburger HA, Klee GG, Pitot HC, Rubin J.
    Am J Gastroenterol; 1997 Dec 11; 92(12):2250-6. PubMed ID: 9399764
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
    Angeletti S, Corleto VD, Schillaci O, Moretti A, Panzuto F, Annibale B, Delle Fave G.
    Ital J Gastroenterol Hepatol; 1999 Dec 11; 31(1):23-7. PubMed ID: 10091100
    [Abstract] [Full Text] [Related]

  • 20. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.
    Shojamanesh H, Gibril F, Louie A, Ojeaburu JV, Bashir S, Abou-Saif A, Jensen RT.
    Cancer; 2002 Jan 15; 94(2):331-43. PubMed ID: 11900219
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.